2023-03-14 08:51:59 ET
- Ultragenyx Pharmaceutical ( NASDAQ: RARE ) promotes Eric Crombez to Chief Medical Officer and executive Vice President succeeding Camille Bedrosian, effective May 1, 2023
- Camille Bedrosian will remain with the company in a full-time strategic advisory role.
- Dr. Crombez joined the company following the acquisition of Dimension Therapeutics in November 2017and currently serves as Chief Medical Officer for gene therapy and inborn errors of metabolism.
For further details see:
Ultragenyx appoints Eric Crombez Chief Medical Officer and executive Vice President